StemCell Therapy

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the second annual Cancer Community (C2) Awards. A part of the YOUR Cancer program, the C2 Awards celebrate grassroots organizations and individuals making impactful change in the cancer community. The program seeks to shine a light upon unsung community heroes who often go unrecognized by traditional awards programs and this year saw nominations from 31 states.

The pace at which oncology care is progressing is both rapid and extraordinary, said Chatrick Paul, Head of US Oncology, AstraZeneca. We know that coming together as a community is essential to advancing cancer care and realizing meaningful change for cancer patients. This could not be more true than now when COVID-19 has disrupted efforts of the healthcare community to screen, test and diagnose cancer patients in a timely manner. We know that together, through this program, we can remove barriers to care, transform health systems and support patients beyond our medicines.

Cancer impacts millions of Americans and is something no one should ever have to experience alone, said Jeremy Abbate, Publisher, Scientific American Custom Media. This years winners and finalists collectively embody the sentiment and purpose of the C2 Awards. We are humbled to share their heartfelt stories of dedication and sacrifice to instill new hope for those across our country facing a cancer diagnosis.

The C2 Awards feature four categories, recognizing the community in the following ways: extending quality care to underserved communities, improving the patient experience, advancing precision medicine and doing something tangible and inspiring for patients. Winners will each receive $50,000 donation to pay forward to a non-profit organization serving the cancer community.

The 2020 Cancer Community Awards Recipients

The C2 Catalyst for Change award celebrates those who significantly improve access to cancer care for underserved populations.

The C2 Catalyst for Care award recognizes those who enhance the experience of care for patients during their cancer treatment.

The C2 Catalyst for Precision Medicine award honors those who improve personalized treatment for cancer patients.

The Presidents Award, selected by AstraZeneca, honors those who make a tangible and inspiring difference for patients and their loved ones.

Nominations were evaluated by an esteemed panel of multidisciplinary community leaders, including Edward Abrahams, PhD, President, Personalized Medicine Coalition; Meghan Gutierrez, CEO, Lymphoma Research Foundation; Erin McAllister, formerly at BioCentury; Audra Moran, President & CEO, Ovarian Cancer Research Alliance; Dr Barbara Gitlitz, MD, Medical Oncologist, Keck School of Medicine of USC; Dr Geoffrey Oxnard, MD, Thoracic Oncologist, Dana-Farber Cancer Institute; Dr Keith Winfrey, MD, MPH, Chief Medical Officer, New Orleans East Louisiana Community Health Center; and Leah Fine, Director, Centers of Excellence Program, GO2 Foundation for Lung Cancer.

More details on finalists and winners can be found here.

About YOUR Cancer

The C2 Awards are part of the YOUR Cancer Program, a broader initiative launched by AstraZeneca to spotlight those at the forefront of cancer research and patient support who are contributing toward eliminating cancer as a cause of death. YOUR CANCER aims to convene, engage, and highlight the full breadth of the oncology community, utilizing four pillars: a digital partnership hub profiling community resources and perspectives, an awards program recognizing the unsung heroes of oncology, state-level roundtables with local policymakers and advocates, and media and speaking engagements profiling community oncology leaders.

About AstraZeneca in Oncology

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients lives and the Companys future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance Oncology as a growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in hematology.

By harnessing the power of four scientific platforms Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates and by championing the development of personalized combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit http://www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

About Scientific American Custom Media

Scientific American's award-winning Custom Media team (SACM) develops targeted, strategic content programs in partnership with corporations, governments, and academic institutions. SACM operates as a division separate from the magazines Board of Editors to create highly engaging, one-of-a-kind media programs for thought-leading audiences. From mini-documentaries or custom events to standalone magazines and native content series, SACM offers its partners opportunities to build compelling and distinct narratives that convey their brand values and unique stories.

See more here:
AstraZeneca Announces Winners and Recognizes Unsung Heroes of Oncology in 2020 Cancer Community (C2) Awards - Business Wire

This entry was posted on October 28, 2020 at 10:52 am and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |